Joshua Bauml, MD, University of Pennsylvania
Articles
Optimizing Testing Strategies in Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
MET Exon 14 Mutations in Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Rebiopsy at Progression of ALK-Rearranged NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Treating ALK-Rearranged Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Trials in ALK-Rearranged Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
TKI Combinations in Metastatic EGFR+ Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Role of Adjuvant Osimertinib in Early Stage NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
ADAURA Trial; Early Stage Non–Small Cell Lung Cancer
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center;Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua Bauml, MD, University of Pennsylvania;Rebecca Heist, MD, Massachusetts General Hospital Cancer Center
August 10th 2020Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
